ProQR Therapeutics/PRQR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About ProQR Therapeutics

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Ticker

PRQR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel De Boer

Employees

157

Headquarters

Leiden, Netherlands

PRQR Metrics

BasicAdvanced
$159M
Market cap
-
P/E ratio
-$0.36
EPS
0.34
Beta
-
Dividend rate
$159M
0.34101
$3.29
$1.11
152K
3.113
38.405
55.214
-18.83%
-57.22%
-23.01%
10.849
4.352
4.202
252.63%
59.31%
0.26%

What the Analysts think about PRQR

Analyst Ratings

Majority rating from 7 analysts.
Buy

PRQR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-165.21% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€4.6M
-25.81%
Net income
-€7.6M
40.74%
Profit margin
-165.21%
89.70%

PRQR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.42%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.10
-€0.07
-€0.07
-€0.09
-
Expected
-€0.11
-€0.09
€0.01
-€0.11
-€0.13
Surprise
-9.79%
-18.02%
-710.93%
-18.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ProQR Therapeutics stock?

ProQR Therapeutics (PRQR) has a market cap of $159M as of June 18, 2024.

What is the P/E ratio for ProQR Therapeutics stock?

The price to earnings (P/E) ratio for ProQR Therapeutics (PRQR) stock is 0 as of June 18, 2024.

Does ProQR Therapeutics stock pay dividends?

No, ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next ProQR Therapeutics dividend payment date?

ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders.

What is the beta indicator for ProQR Therapeutics?

ProQR Therapeutics (PRQR) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ProQR Therapeutics stock price target?

The target price for ProQR Therapeutics (PRQR) stock is $4.21, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ProQR Therapeutics stock

Buy or sell ProQR Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing